Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 21 of 21 publications.

Wolf J, Garon EB, Groen HJM, Tan DSW, Gilloteau I, Le Mouhaer S, Hampe M, Cai C, Chassot-Agostinho C, Reynolds M, Sherif B, Heist RS. Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: results from the GEOMETRY mono-1 study. Eur J Cancer. 2023 Apr;183:98-108. doi: 10.1016/j.ejca.2022.10.030

Banjara B, Poudel N, Garza KB, Westrick S, Whitley HP, Redden D, Ngorsuraches S. Patients' preferences for sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists. Patient Prefer Adherence. 2022 Dec 28;16:3415-28. doi: 10.2147/PPA.S391719

Smith MR, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Mohamed AF, Odom D, Bartsch J, Snapir A, Sarapohja T, Fizazi K. Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the phase III ARAMIS trial. Eur J Cancer. 2021 Jul 14;154:138-46.

Musetti S, Leaf H. Tinagl1 gene therapy for tumor-wide remodeling of triple negative breast cancer. Poster presented at the 2020 32nd EORTC-NCI-AACR Symposium; October 26, 2020. [abstract] Eur J Cancer. 2020 Oct 1; 138(2):S37-8. doi: 10.1016/S0959-8049(20)31172-2

Fifer S, Galinsky J, Richard S. Myeloma patient value mapping: a discrete choice experiment on myeloma treatment preferences in the UK. Patient Prefer Adherence. 2020 Jul 28;14:1283-493. doi: 10.2147/PPA.S259612

Aletaha D, Husni ME, Merola JF, Ranza R, Bertheussen H, Lippe R, Young P, Cappelleri JC, Brown TM, Ervin C, Hsu M-A, Fallon L. Treatment mode preferences in psoriatic arthritis: a qualitative multi-country study. Patient Prefer Adherence. 2020 Jun 8;2020(14):949-61. doi: 10.2147/PPA.S242336

Taylor PC, Betteridge N, Brown TM, Woolcott J, Kivitz AJ, Zerbini C, Whalley D, Olayinka-Amao O, Chen C, Dahl P, Ponce de Leon D, Gruben D, Fallon L. Treatment mode preferences in rheumatoid arthritis: moving toward shared decision-making. Patient Prefer Adherence. 2020 Jan 20;14:119-31. doi: 10.2147/PPA.S220714

Novick D, Montgomery W, Treuer T, Koyanagi A, Aguado J, Kraemer A, Haro JM. Comparison of clinical outcomes with orodispersible versus standard oral olanzapine tablets in nonadherent patients with schizophrenia or bipolar disorder. Patient Prefer Adherence. 2017 Jun 6;11:1019-25. doi: 10.2147/PPA.S124581

Mankowski C, Ikenwilo D, Heidenreich S, Ryan M, Nazir J, Newman C, Watson V. Men's preferences for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: a discrete choice experiment. Patient Prefer Adherence. 2016 Nov 24;10:2407-17. doi: 10.2147/PPA.S112161

Caballero-Banos M, Benitez-Ribas D, Tabera J, Varea S, Vilana R, Bianchi L, Ayuso JR, Pages M, Carrera G, Cuatrecasas M, Martin-Richard M, Cid J, Lozano M, Castells A, Garcia-Albeniz X, Maurel J, Vilella R. Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients. Eur J Cancer. 2016 Sep;64:167-74. doi: 10.1016/j.ejca.2016.06.008

Boklage SH, Mangel AW, Ramamohan V, Mladsi D, Wang T. Cost-effectiveness analysis of universal noninvasive testing for post-treatment confirmation of Helicobacter pylori eradication and the impact of patient adherence. Patient Prefer Adherence. 2016 Jun 8;2016(10):1025-35. doi: 10.2147/PPA.S102760

Boklage SH, Mangel AW, Ramamohan V, Mladsi D, Wang T. Impact of patient adherence on the cost-effectiveness of noninvasive tests for the initial diagnosis of Helicobacter pylori infection in the United States. Patient Prefer Adherence. 2016 Jan 21;10:45-55. doi: 10.2147/PPA.S93320.

Garcia-Albeniz X, Chan JM, Paciorek A, Logan RW, Kenfield SA, Cooperberg MR, Carroll PR, Hernan MA. Immediate vs. deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study. Eur J Cancer. 2015 May;51(7):817-24. doi: 10.1016/j.ejca.2015.03.003

Graham CN, Hechmati G, Hjelmgren J, de Liege F, Lanier J, Knox H, Barber B. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer. 2014 Nov;50(16):2791-801. doi: 10.1016/j.ejca.2014.08.016

Alonso-Espinaco V, Cuatrecasas M, Alonso V, Escudero P, Marmol M, Horndler C, Ortego J, Gallego R, Codony-Servat J, Garcia-Albeniz X, Jares P, Castells A, Lozano JJ, Rosell R, Maurel J. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy. Eur J Cancer. 2014 Jul;50(11):1973-81. doi: 10.1016/j.ejca.2014.04.019

Herring WL, Herrmann JW. The single-day surgery scheduling problem: sequential decision-making and threshold-based heuristics. OR spectrum: quantitative approaches in management. 2012 Apr 1;34(2):429-59.

Kauf TL, Davis KL, Earnshaw SR, Davis EA. Spillover adherence effects of fixed-dose combination HIV therapy. Patient Prefer Adherence. 2012 Feb 1;6:155-64.

Sherrill B, Akhras K, Kaye J, Sandin R, Cappelleri J, Heyes A, Chen C. Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology. Poster presented at the European Multidisciplinary Cancer Congress of the European Cancer Organization; September 24, 2011. Stockholm, Sweden. [abstract] Eur J Cancer. 2011 Sep 1; 47(Suppl. 1):S261.

Sharp L, Carsin AE, Cronin-Fenton DP, O'Driscoll D, Comber H. Is there under-treatment of pancreatic cancer? Evidence from a population-based study in Ireland. Eur J Cancer. 2009 May;45(8):1450-9. doi: 10.1016/j.ejca.2009.01.033

Cronin-Fenton DP, Sharp L, Carsin AE, Comber H. Patterns of care and effects on mortality for cancers of the oesophagus and gastric cardia: a population-based study. Eur J Cancer. 2007 Feb;43(3):565-75. doi: 10.1016/j.ejca.2006.10.011

Fortuny J, Benavente Y, Bosch R, García-Villanueva M, de Sevilla AF, de Sanjose S. Type 2 diabetes mellitus, its treatment and risk for lymphoma. Eur J Cancer. 2005 Aug;41(12):1782-7. doi: 10.1016/j.ejca.2005.04.032